FNY Investment Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
+7,385
New +$998K 0.42% 59
2025
Q4
Sell
-15,133
Closed -$1.52M 1543
2025
Q3
$1.52M Buy
+15,133
New +$1.36M 0.49% 53
2024
Q3
Sell
-10
Closed 839
2024
Q2
$0 Sell
10
-2,882
-100% -$258K ﹤0.01% 843
2024
Q1
$274 Buy
+2,892
New +$268K 0.17% 105
2023
Q1
Sell
-100
Closed -$8K 760
2022
Q4
$8K Buy
+100
New +$8.1K 0.01% 327
2022
Q3
Sell
-2,000
Closed -$148K 878
2022
Q2
$148K Buy
2,000
+1,245
+165% +$93.5K 0.11% 126
2022
Q1
$67K Buy
+755
New +$69.7K 0.06% 215
2020
Q2
Sell
-10,000
Closed -$774K 614
2020
Q1
$774K Buy
+10,000
New +$885K 0.59% 43

Other funds holding XBI

FNY Investment Advisers's XBI Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 7,385 shares worth $1.17M. The stake represents 0.42% of the portfolio and ranks #59 among its holdings. This is a return to the name: FNY Investment Advisers previously reported a position in XBI as recently as Q3 2025.

FNY Investment Advisers first reported a position in XBI in Q1 2020 and has held it in 8 quarters since. The position peaked at $1.52M in Q3 2025. 519 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • FNY Investment Advisers held 7,385 shares of State Street SPDR S&P Biotech ETF worth $1.17M as of Q2 2026.
  • State Street SPDR S&P Biotech ETF was a new FNY Investment Advisers position in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.42% of FNY Investment Advisers's portfolio in Q2 2026, its #59 holding.
  • FNY Investment Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 8 quarters since.
  • FNY Investment Advisers's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q3 2025.
  • 519 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.